person
Herve L.
- Country
- France
- Department
- Pneumology Department
Research Overview
assignment
43
Clinical Trials ·
- Dose-Escalation Study of Zongertinib in Patients with Advanced Non-Small Cell Lung Cancer and Solid Tumors with HER2 Aberrations
- Phase I/IIa Study of Inhaled CIS-DPI as Adjunctive Therapy in Stage IV Non-Small Cell Lung Cancer Patients
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
318
Sites with multiple studies
Has run more than one trial at 318 of 548 partner sites.
Specializations
Advanced NSCLC Treatment
Specializes in investigating non-small cell lung cancer treatments, with particular focus on targeted therapies for various genetic mutations including EGFR, ROS1, and ALK alterations.
- Mutation-specific therapies
- Novel therapeutic combinations
- Targeted molecular approaches
Immunotherapy Research
Focuses on innovative immunotherapy approaches in lung cancer treatment, including studies of checkpoint inhibitors and their combinations with conventional therapies.
- Combination immunotherapy strategies
- Novel immune checkpoint pathways
- Biomarker-driven treatment selection
Early-Stage Disease Management
Investigates treatment strategies for early-stage lung cancer, including neoadjuvant therapy approaches and surgical intervention protocols.
- Perioperative treatment optimization
- Multimodal therapy approaches
- Disease recurrence prevention
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.